- Mean change in visual acuity [LogMAR] score from baseline to endpoint compared to placebo (at week 12 or last LogMAR assessment conducted at or after week 8 of the treatment period) [clinicaltrials_resource:8d9c820cad86e63fff679a0b72954ff2]
Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
- Mean change in visual acuity [LogMAR] score from baseline to endpoint compared to placebo (at week 12 or last LogMAR assessment conducted at or after week 8 of the treatment period) [clinicaltrials_resource:8d9c820cad86e63fff679a0b72954ff2]
Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
Bio2RDF identifier
8d9c820cad86e63fff679a0b72954ff2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:8d9c820cad86e63fff679a0b72954ff2
measure [clinicaltrials_vocabulary:measure]
- Mean change in visual acuity ...... o endpoint compared to placebo
time frame [clinicaltrials_vocabulary:time-frame]
(at week 12 or last LogMAR ass ...... eek 8 of the treatment period)
description
Albumin (Human) 20% or 25% wil ...... a final concentration of 0.1%.
identifier
clinicaltrials_resource:8d9c820cad86e63fff679a0b72954ff2
title
- Mean change in visual acuity ...... eek 8 of the treatment period)
@en
type
label
- Mean change in visual acuity ...... c820cad86e63fff679a0b72954ff2]
@en